Lannett Co (Lannett Co) Tax Provision : $-0.6 Mil (TTM As of Mar. 2023)

View and export this data going back to 1994. Start your Free Trial

What is Lannett Co Tax Provision?

Lannett Co's tax provision for the three months ended in Mar. 2023 was $-0.0 Mil. Its tax provision for the trailing twelve months (TTM) ended in Mar. 2023 was $-0.6 Mil.

Lannett Co Tax Provision Historical Data

The historical data trend for Lannett Co's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lannett Co Tax Provision Chart

Lannett Co Annual Data

Trend

Jun13

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Tax Provision

Get a 7-Day Free Trial

-22.40

74.14

15.26

-60.63

2.30

Lannett Co Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Tax Provision	Get a 7-Day Free Trial															1.37	-0.49	-0.03	-0.03	-0.03

Lannett Co Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.6 Mil.

Lannett Co (Lannett Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lannett Co Inc (OTCPK:LCINQ) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

N/A

Address

1150 Northbrook Drive, Suite 155, Trevose, PA, USA, 19053

Website

https://www.lannett.com

Lannett Co Inc develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products. It offers solid oral, extended-release, topical, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, patch, foam, buccal, sublingual, soft gel, and injectable dosages. In addition, the company also provides its products for various medical indications comprising glaucoma, gastrointestinal, migraine, obesity, respiratory, and others. It operates in the segment of generic pharmaceuticals. Its customers include generic pharmaceutical distributors, drug wholesalers, chain drug stores, private label distributors, mail-order pharmacies, and others.

Executives

John C Chapman	director	9000 STATE ROAD, PHILADELPHIA PA 19136
Timothy C Crew	officer: Chief Executive Officer	9000 STATE ROAD, PHILADELPHIA PA 19136
Patrick G Lepore	director	17-17 ROUTE 208 N, FAIRLAWN NJ 07410
Melissa Rewolinski	director	9000 STATE ROAD, PHILADELPHIA PA 19136
Jeffrey Farber	officer: Secretary
Samuel H Israel	officer: Chief Legal Officer	9000 STATE ROAD, PHILADELPHIA PA 19136
John Abt	officer: Vice President of Quality	9000 STATE ROAD, PHILADELPHIA PA 19136
John Kozlowski	officer: Chief Operating Officer	9000 STATE ROAD, PHILADELPHIA PA 19136
David A Drabik	director	9000 STATE RD, PHILADELPHIA PA 19136
Paul Taveira	director	9000 STATE ROAD, PHILADELPHIA PA 19136
Albert Iii Paonessa	director	9852 NW 2ND COURT, PLANTATION FL 33324
Kevin Smith	other: Vice President
Maureen Cavanaugh	officer: Senior Vice President and CCOO	9000 STATE ROAD, PHILADELPHIA PA 19136
David Farber	officer: Treasurer
Arthur P Bedrosian	officer: President	P O BOX D 1400, POMONA NY 10970